Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Precision BioSciences ( (DTIL) ).
On August 26, 2025, Precision BioSciences amended and restated employment agreements for its key executives to retain them and reflect updated compensation terms. These agreements include provisions for termination without cause and require funding of severance and expenses in an escrow account, with interest and unused funds benefiting the company.
The most recent analyst rating on (DTIL) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.
Spark’s Take on DTIL Stock
According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.
The overall stock score is primarily impacted by significant financial challenges, including revenue decline and profitability issues. However, the promising Phase 1 trial results for PBGENE-HBV provide a positive outlook for future growth. Technical indicators show moderate strength, but poor valuation due to negative earnings remains a concern.
To see Spark’s full report on DTIL stock, click here.
More about Precision BioSciences
Precision BioSciences operates in the biotechnology industry, focusing on developing gene editing technologies and therapies.
Average Trading Volume: 273,306
Technical Sentiment Signal: Sell
Current Market Cap: $57.76M
Learn more about DTIL stock on TipRanks’ Stock Analysis page.